Fig. 3From: The molecular characteristics of spinal cord gliomas with or without H3 K27M mutationMGMT promoter methylation status and chemotherapy responses of spinal cord astrocytomas. a The methylation levels of MGMT promoter CpGs 76–79 and the clinicopathological features of spinal cord gliomas. b The impact of TMZ treatment on the survival of patients with WHO 2016 grade IV gliomasBack to article page